Product
pNGVL3-hICD vaccine
1 clinical trial
5 indications
Indication
Breast Cancer (HER2-positive)Indication
Ovarian Epithelial Cancer, Stage IIIIndication
Ovarian Germ Cell TumorIndication
Breast CancerIndication
Ovarian Epithelial CancerClinical trial
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing TumorsStatus: Active (not recruiting), Estimated PCD: 2010-03-01